Critical Path Institute® (C-Path) will host its 2026 Global Impact Conference (CGIC) this September at the Washington ...

In my previous article, I discussed how AI is rapidly transforming the drug discovery process, significantly accelerating timelines and reducing costs. However, while AI's potential in this domain is ...

AI can speed up drug discovery and decrease attrition rates in the clinic, but it is important to recognize that both are ...

Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study) The following represents ...

The pharmaceutical industry is experiencing its own “DeepSeek moment,” according to science writer Hiya Jain. Just as the upstart AI breakthrough caught Silicon Valley off-guard, China is emerging as ...

While rare disease research has advanced significantly, related expertise and data are scattered across too many disconnected places.

FDA instability, staff turnover, and evolving review standards are reshaping drug development. Richard Pazdur, formerly with ...

Medicine stands at a remarkable crossroads. The explosive growth in specialty drug development marks a new golden age of therapeutic innovation. In 1990 there were just 10 specialty drugs on the ...

The US Food and Drug Administration (FDA) this week released a new draft guidance on the development of new drugs intended to treat pulmonary tuberculosis (TB), a bacterially-transmitted disease that ...